0.6942
Io Biotech Inc Borsa (IOBT) Ultime notizie
IO Biotech (IOBT) Stock Analysis Report | Financials & Insights - Benzinga
How does IO Biotech Inc (IOBT) change from a tortoise to a hare? - Setenews
Will IO Biotech Inc. stock reach all time highs in 2025July 2025 Levels & Growth Focused Stock Reports - BỘ NỘI VỤ
Research Recommendations For IO Biotech Inc (IOBT): Here is What You Should Know - fostersleader.com
Analyst Downgrade: How IO Biotech Inc. stock benefits from strong dollarJuly 2025 Movers & Free Growth Oriented Trading Recommendations - moha.gov.vn
How strong is IO Biotech Inc. stock balance sheetMarket Performance Recap & Long-Term Safe Investment Plans - BỘ NỘI VỤ
Aug Wrap: What margin trends mean for IO Biotech Inc. stockJuly 2025 Decliners & Real-Time Volume Analysis Alerts - BỘ NỘI VỤ
IO Biotech Announces Participation in Upcoming December Investor Conferences - The Manila Times
IO Biotech (Nasdaq: IOBT) to Join Evercore, Piper Sandler December Investor Events - Stock Titan
IOBTRemeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For - mx.advfn.com
It makes sense and dollars to buy IO Biotech Inc (IOBT) stock - Setenews
IO Biotech (NASDAQ:IOBT) Stock Rating Upgraded by Wall Street Zen - Defense World
Ligand Pharmaceuticals (NASDAQ:LGND) and IO Biotech (NASDAQ:IOBT) Financial Review - Defense World
IO Biotech announces resignation of chief accounting officer and new appointment - Investing.com Australia
IO Biotech Announces Resignation of Chief Accounting Officer - MSN
IO Biotech announces resignation of chief accounting officer and new appointment By Investing.com - Investing.com South Africa
IO Biotech Announces Management Changes - TradingView
[8-K] IO Biotech, Inc. Reports Material Event | IOBT SEC FilingForm 8-K - Stock Titan
IO Biotech, Inc. Announces Executive Changes - MarketScreener
Can IO Biotech Inc. stock withstand economic slowdown2025 Retail Activity & Risk Controlled Daily Trade Plans - newser.com
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For - The Spec
Piper Sandler reiterates Overweight rating on IO Biotech stock By Investing.com - Investing.com South Africa
Is IO Biotech Inc. stock entering bullish territoryJuly 2025 Review & Fast Gaining Stock Reports - newser.com
Is IO Biotech Inc. stock a top momentum playWeekly Stock Analysis & Daily Price Action Insights - newser.com
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why - Yahoo Finance
Will IO Biotech Inc. stock deliver long term returns2025 Support & Resistance & High Conviction Buy Zone Picks - newser.com
Piper Sandler reiterates Overweight rating on IO Biotech stock - Investing.com India
IO Biotech Inc. (IOBT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is IO Biotech Inc. stock safe for conservative investorsPortfolio Return Summary & Reliable Volume Spike Alerts - newser.com
IO Biotech’s Q3 2025: Progress in Cancer Vaccine Trials - MSN
IO Biotech Presents at Jefferies Global Healthcare Conference - MSN
IO Biotech Inc (IOBT) is looking forward to a strong quarter - Setenews
IO Biotech, Inc. Updates on Cylembio Phase 3 Trial Results - TradingView
Will IO Biotech Inc. see short term momentum2025 Top Gainers & Technical Confirmation Trade Alerts - newser.com
Sector ETF performance correlation with IO Biotech Inc.Market Trend Review & Smart Allocation Stock Reports - newser.com
Is IO Biotech Inc. meeting your algorithmic filter criteriaEarnings Miss & High Conviction Investment Ideas - newser.com
What moving averages say about IO Biotech Inc.Stock Surge & Low Risk High Reward Trade Ideas - newser.com
IO Biotech’s Hold Rating Amid Financial and Regulatory Uncertainty - TipRanks
Will IO Biotech Inc. stock outperform tech sector in 2025Bull Run & Weekly High Momentum Picks - newser.com
IO Biotech, Inc.Common Stock (Nasdaq:IOBT) Detailed Stock Data | PRN_FinancialWrapper | PR Newswire - Markets Financial Content
Will IO Biotech Inc. stock benefit from green energy trendsWeekly Volume Report & Free Risk Controlled Daily Trade Plans - Fundação Cultural do Pará
IO Biotech, Inc. SEC 10-Q Report - TradingView
IO Biotech reports $8.4 mln Q3 net loss - MarketScreener
IO Biotech Reports Phase 3 Clinical Trial Data for Cylembio in Advanced Melanoma and Third Quarter 2025 Financial Results - Quiver Quantitative
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights - The Manila Times
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):